Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05696353 · ClinicalTrials.gov registry record · Phase 3

Teen Driving Translation Study (NIH)

A Phase 3 study of Communication and Recidivism, sponsored by Ginger Yang.

Recruiting
Registry status
Phase 3
Development phase
580
Enrollment target
1
Study location

NCT05696353 is a Phase 3 study of Communication and Recidivism that is actively recruiting participants, run by Ginger Yang. The registered enrollment target is 580 participants, below the 1,404-participant average among 34 other Communication trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05696353, a Phase 3 study of Communication and Recidivism, is actively recruiting participants, sponsored by Ginger Yang.

RECRUITING
Registry status
Phase 3
Development phase
580 participants
Enrollment target
1
Study location

Study Summary

To translate our evidence-based, parent-engagement safe teen driving intervention to a high-risk, rural and urban teen drivers with a traffic violation, and to test the implementation, effectiveness, and cost-effectiveness of the proposed intervention.

Interventions

  • COMBINATION_PRODUCT In-vehicle Device
  • BEHAVIORAL Expert-Delivered Parent Communication Training
  • BEHAVIORAL Peer-Delivered Parent Communication Training

Study Locations (1)

Ohio

  • Nationwide Children's Hospital - Columbus

Trial Details

FieldValue
Enrollment Target 580 participants
Start Date 2022-11-17
Est. Completion 2026-08-31
Phase Phase 3

Sponsor

Ginger Yang

3 total trials

What the Registry Record Tells You About NCT05696353

The ClinicalTrials.gov registry entry for NCT05696353 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 580 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,404-participant average among 34 other Communication trials with a reported enrollment target (59% lower). The listed sponsor is Ginger Yang, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Communication appearing as the primary indexed condition, and to 3 interventions - of which In-vehicle Device is the first listed.

NCT05696353 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT05696353 about?

NCT05696353 is a clinical study titled "Teen Driving Translation Study (NIH)". To translate our evidence-based, parent-engagement safe teen driving intervention to a high-risk, rural and urban teen drivers with a traffic violation, and to test the implementation, effectiveness, and cost-effectiveness of the proposed intervention.

What is the current status of trial NCT05696353?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 580 participants. The study started on 2022-11-17. Estimated completion is 2026-08-31.

What conditions does trial NCT05696353 study?

This clinical trial studies the following conditions: Communication, Recidivism, Drive, Feedback, Psychological.

What interventions are being tested in trial NCT05696353?

The interventions under investigation include: In-vehicle Device (COMBINATION_PRODUCT), Expert-Delivered Parent Communication Training (BEHAVIORAL), Peer-Delivered Parent Communication Training (BEHAVIORAL).

Who is sponsoring clinical trial NCT05696353?

This trial is sponsored by Ginger Yang, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05696353 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Communication

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.